UK firm GSK to pay $2.2bn over Zantac cancer claims
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer. The firm announced that it has reached agreements with 10 law firms who represent around 80,
Zantac maker GSK agrees to pay $2.3 bn in US settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK reaches $2.2bn heartburn medication Zantac settlement in US
GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK to settle 80,000 Zantac cases for up to $2.2 billion
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
GSK Reaches $2.2 Bln Settlement Over Zantac Liability Cases
GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000)
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Zantac Maker GSK Says It Reaches $2.3 Bn Settlement In US
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK agrees to settle 80,000 Zantac lawsuits for $2.2B
GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion. The agreements involve firms representing 93% of the pending cases in the U.
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
STAT10h
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...
Thousands of cancer patients in line to share £1.7bn as GSK settles Zantac cases
Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...
FiercePharma10h
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.